CG Oncology falls below the minimum quality threshold with a single-asset pipeline dependency, severe cash consumption at more than 2,000% of revenue, three out of four recent earnings misses, and a recent C-suite change — collectively presenting a risk profile that outweighs the 31.9% upside to the analyst target.
Thesis pillars
- Single Asset Pipeline Concentration↑Improving
- Quality Below Minimum Threshold↑Improving
- Severe Cash Burn Rate→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 27, 2026
CG Oncology, Inc. (CGON) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $63.96: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Below-average business quality; Below long-term trend.
CG Oncology is a clinical-stage biopharmaceutical company with a single product candidate, cretostimogene, in Phase 3 trials for non-muscle invasive bladder cancer. The company has no commercial revenue and funds operations through equity financing, having initiated a Biologics... Read more
Sell if holding. Engine safety override at $63.96: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Below-average business quality; Below long-term trend. Chart setup: RSI 53 mid-range, Bollinger mid-band. Score 5.3/10, moderate confidence.
Passes 6/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About CG Oncology, Inc.
About CG Oncology, Inc.
CG Oncology's entire clinical program centers on cretostimogene grenadenorepvec, an oncolytic immunotherapy in Phase 3 development for non-muscle invasive bladder cancer (NMIBC). The company initiated a Biologics License Application submission to the FDA in Q4 2025 — expected to be completed in 2026 — based on Phase 3 BOND-003 Cohort C data showing a 75.5% complete response rate at any time in high-risk BCG-unresponsive patients with carcinoma in situ. Cretostimogene holds both FDA Fast Track and Breakthrough Therapy designations, targeting an addressable population estimated at up to 25,000 U.S. patients for the initial indication.
CG Oncology's development program spans two Phase 3 registrational trials and multiple Phase 2 cohorts. BOND-003 Cohort C targets high-risk BCG-unresponsive NMIBC; enrollment is complete and the BLA submission is underway. PIVOT-006, the first randomized registrational trial in intermediate-risk NMIBC, completed enrollment in Q3 2025, targeting an additional estimated 50,000 U.S. addressable patients. The CORE-008 Phase 2 multi-cohort trial evaluates BCG-exposed and BCG-naïve populations, including a combination arm with gemcitabine initiated in April 2025. Manufacturing of cretostimogene for clinical supply relies on Biovire and third-party contractors. The company is simultaneously building a U.S. commercial organization focused on large academic urology practices in major metropolitan areas, where the 10-K notes that a high volume of bladder cancer patients is concentrated — potentially enabling commercialization with a relatively small salesforce. As of January 30, 2026, cretostimogene had been administered in over 740 patients with no Grade 4 or 5 treatment-related adverse events observed.
Show full overview
The entire near-term value of CG Oncology depends on the FDA's review of the BOND-003 Cohort C BLA. If the FDA requests additional data, issues a Complete Response Letter, or does not accept a single-arm complete response rate as sufficient for full approval, the company has no alternative revenue source. The 10-K states explicitly that cretostimogene is the company's only product candidate and that failure to advance it would materially harm the business. In May 2026, the company's President and COO Ambaw Bellete agreed to separate effective June 30, 2026, with Arthur Kuan appointed President and a Chief Commercial Officer search initiated — a leadership transition that could affect pre-commercial readiness ahead of a potential 2026 approval decision.
See also: Healthcare · Biotechnology
From CG Oncology, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-10-29Recent Developments — CG Oncology, Inc.
Latest news
- NEWS 10 Health Care Stocks Whale Activity In Today’s Session — benzinga Aug 24, 2026 neutral
- NEWS RBC Capital Maintains Outperform on CG Oncology, Lowers Price Target to $79 — benzinga Aug 7, 2026 positive
- NEWS Piper Sandler Maintains Overweight on CG Oncology, Raises Price Target to $85 — benzinga Aug 7, 2026 neutral
- NEWS Truist Securities Maintains Buy on CG Oncology, Raises Price Target to $85 — benzinga Aug 7, 2026 positive
- NEWS CG Oncology Q2 EPS $(0.90) Misses $(0.67) Estimate, Sales $1.157M Beat $360.417K Estimate — benzinga Aug 6, 2026 negative
Generated 2026-10-29T11:14:31Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinecretostimogene10-K Item 1A: 'We currently depend entirely on the success of cretostimogene, which is our only product candidate'
- HIGHSupplierBiovire10-K Item 1A: 'We rely on Biovire and third parties for the manufacture and shipping of cretostimogene for clinical development'
Material Events(8-K, last 90d)
- 2026-05-26Item 5.02MEDIUMAmbaw Bellete, President & COO, agreed to separate effective June 30, 2026. Arthur Kuan appointed President in addition to current roles. Company initiated search for Chief Commercial Officer. Partial succession — COO role not filled.SEC filing →
- 2026-04-13Item 5.02LOWJim DeTore appointed as permanent CFO effective April 13, 2026, converting from Interim Principal Financial and Accounting Officer role held since November 2025. Annual base salary $520,000, target bonus 45%. No prior CFO departure at this event.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $63.96: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 3.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 10%; Below-average business quality; Below long-term trend. Chart setup: RSI 53 mid-range, Bollinger mid-band. Prior stop was $59.48. Score 5.3/10, moderate confidence.
Analyst target: $79.24 (+23.9% upside). Prior stop was $59.48. Stop-loss: $59.48.
Concentration risk — Pipeline: cretostimogene; Concentration risk — Supplier: Biovire; Quality below floor (1.8 < 4.0).
CG Oncology, Inc. trades at a P/E of N/A (forward -21.2). TrendMatrix value score: 7.5/10. Verdict: Sell.
21 analysts cover CGON with a consensus score of 4.1/5. Average price target: $91.
What does CG Oncology, Inc. do?CG Oncology is a clinical-stage biopharmaceutical company with a single product candidate, cretostimogene, in Phase 3...
CG Oncology is a clinical-stage biopharmaceutical company with a single product candidate, cretostimogene, in Phase 3 trials for non-muscle invasive bladder cancer. The company has no commercial revenue and funds operations through equity financing, having initiated a Biologics License Application submission to the FDA in Q4 2025 with completion expected in 2026. Cretostimogene holds FDA Fast Track and Breakthrough Therapy designations for BCG-unresponsive NMIBC.